Expert perspectives on reimbursement for high-cost therapies, both chronic and curative, were discussd at the recent Biotechnology Innovation Organization virtual international convention. The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability, the role of patient advocacy, value-based purchasing, and ICER value assessments
read full article ›